Skip to content

Advertisement

  • Poster presentation
  • Open Access

Auto-immune thrombocytopenia after Measles Mumps Rubella MMR vaccination: molecular mimicry of measles virus phosphoprotein with platelet gpIIb

Retrovirology20107 (Suppl 1) :P173

https://doi.org/10.1186/1742-4690-7-S1-P173

  • Published:

Keywords

  • Thrombocytopenia
  • Measle
  • Rubella
  • Mumps
  • Measle Virus

Background

MMR vaccination is complicated by rare cases of auto-immune purpura or thrombocytopenia in a chronological delay of about 10-24 days, which corresponds to the rise of antibodies (Autret E, 1996; Vlacha V, 1996). We have demonstrated that in the cases of HIV-1, Parvovirus B19, Chikungunya virus, Leptospirosis, the culprit is an epitope localized on the platelet gpIIIaIIb, centred by a phenylalanine-proline (Tran MKG, ISHEID Toulon 2002); these auto-antibodies are very powerful and induce in mice a thrombocytopenia; allo-immunisation from mother to the newborn has the same epitope on gpIIIaIIb (Brouk H, 2009). We continue the same direction of research for MMR vaccine.

Methods

Comparison of amino acid sequences between gpIIIaIIb and viruses (measles, mumps and rubella).

Results

There is a molecular mimicry between gpIIb (P08514) and measles virus (strain MVi/Victoria.Aus/12.99) Phosphoprotein P (ABV24494) (Bankamp B, 2008), Table 1.

Tabele 1

platelet gpIIb 782

RGNSFP

Measles virus P protein

199-RGNSFP-204

Discussion

The occurrence of thrombocytopenia 2 or 3 weeks after MMR vaccination is an auto-immune phenomenon, on a peculiar genetic background prone to make auto-antibodies against phenylalanine-proline containing epitopes. MMR vaccine must be avoided in these patients with idiopathic thrombocytopenia (Drachtman RA, 1994). The chronological argument is by itself convincing and confirmed here by the biological finding of the causal epitope on platelet. Thus we must be very cautious in presence of a MMR vaccine clinical auto-immune complication (such as autism) (Wakefield AJ) and not discard it as a simple coincidence, but rather try to elucidate its mechanism and genetics (HLA-DR4). The gpIIIaIIb epitope may serve as a chelating hapten for treatment.

Authors’ Affiliations

(1)
University of Auvergne, Hotel-Dieu Hospital, Clermont-Ferrand, France
(2)
Association Positifs, Paris, France

Copyright

© Tran et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement